ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102

Also written as “TQB2102 for injection”, “TQB2102 for Injection” and “TQB2102 Injection”.

In Sino Biopharmaceutical’s pipeline, HER2双抗ADC. Its studies are mostly in Breast Neoplasms · Biliary Tract Neoplasms · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by Sino Biopharmaceutical.

Drug pageAnti-HER2/Topoisomerase I Inhibitor ADC TQB2102: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 16, 202413 company-led studies, 12 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical1312 open or runningphase 3since Aug 16, 2024Feb 10, 2023Jan 2027phase 3 · NCT06561607
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2102, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2023First study: phase 1 study in Advanced CancerFirst studyNCT05735496 · 219 enrolled · China
  2. Oct 30, 2023Phase 1 study in Breast NeoplasmsNCT06115902 · 153 enrolled · China
  3. May 22, 2024Phase 2 study in Biliary Tract NeoplasmsNCT06431490 · 102 planned · China
  4. Jun 6, 2024Phase 2 study in Breast NeoplasmsNCT06452706 · 42 planned · China
  5. Jul 4, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06496490 · 270 planned · China
  6. Aug 16, 2024Phase 3 study in Breast NeoplasmsNCT06561607 · 542 enrolled · China
  7. Jan 6, 20252 phase 2 studiesNCT06767800, NCT06798207
  8. May 21, 20252 phase 3 studies in Breast NeoplasmsNCT07003074, NCT07008976
  9. Jun 20, 2025Phase 3 study in HER2-positive Breast CancerNCT07043725 · 544 planned · China
  10. Mar 6, 2026Phase 3 study in HER2 IHC3+ Advanced Colorectal CancerNCT07483684 · 142 planned · China
  11. Mar 25, 2026Phase 2 study in Advanced Solid TumorNCT07512583 · 178 planned · China

Ahead

  1. Jan 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06561607
  2. May 2027Primary completion: phase 2 study in Biliary Tract NeoplasmsNCT06431490
  3. Aug 2027Primary completion: phase 3 study in HER2 IHC3+ Advanced Colorectal CancerNCT07483684
  4. Sep 2027Primary completion: phase 3 study in HER2-positive Breast CancerNCT07043725

TargetBeta

“HER2双抗ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07512583Advanced Solid Tumor · China2RecruitingMar 2028178
NCT07483684HER2 IHC3+ Advanced Colorectal Cancer · China3Not yet recruitingAug 2027142
NCT07043725HER2-positive Breast Cancer · China3RecruitingSep 2027544
NCT07008976Breast Neoplasms · China3RecruitingMar 2028246
NCT07003074Breast Neoplasms · China3RecruitingJul 2029642
NCT06798207Gynecological Tumors · China2RecruitingMay 2026170
NCT06767800Gastroesophageal Adenocarcinoma · China2RecruitingSep 2026204
NCT06561607Breast Neoplasms · China3Active, not recruitingJan 2027542
NCT06496490Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 2026270
NCT06452706Breast Neoplasms · China2RecruitingJun 202642
NCT06431490Biliary Tract Neoplasms · China2RecruitingMay 2027102
NCT06115902Breast Neoplasms · China1CompletedFeb 1, 2025153
NCT05735496Advanced Cancer · China1Active, not recruitingJul 21, 2025219

How it is read

Names in the registry

  • “TQB2102 for injection”, 6 entries
  • “TQB2102 for Injection”, 2 entries
  • “TQB2102 Injection”, 2 entries
  • “TQB2930 injection+TQB2102 for injection”, 1 entry
  • “TQB2102 for injection combined with Benmelstobart injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.